Qyuns Therapeutics Co., Ltd.
Qyuns Therapeutics Co., Ltd. (HKSE: 2509) is trading at HK$16.77, about ₹205 at today's HKD/INR rate, as of 25 Sep 2026, 3:30 AM ET, down 0.65% today. Indian residents can buy Qyuns Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$16.56
Today's high
HK$16.96
52 week low
HK$13.21
52 week high
HK$36.50
2509 opened at HK$16.63, closed previously at HK$16.88, and has traded between HK$13.21 and HK$36.50 over the past 52 weeks.
About
Qyuns Therapeutics Co., Ltd., a biotechnology company established in 2015 and headquartered in Taizhou, China, is focused on the discovery and clinical advancement of biologic therapies. Its primary mission is to address autoimmune and allergic diseases within the People's Republic of China. The company boasts a robust pipeline of investigational treatments. Its lead candidate, QX002N, an interleukin (IL)-17A inhibitor, is currently undergoing Phase III clinical trials for the management of ankylosing spondylitis and lupus nephritis. Another key asset, QX005N, a monoclonal antibody engineered to block IL-4Ra, has successfully concluded its Phase II clinical development. This compound targets a wide array of conditions, including atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). Further advanced programs include QX001S, an IL-12/IL-23p40 inhibitor, also in Phase III trials for psoriasis (Ps) and inflammatory bowel diseases such as ulcerative colitis/Crohn's disease (CD). QX004N, an IL-23p19 inhibitor, is progressing through Phase II for Ps and CD. Additionally, early-stage clinical development encompasses QX006N, an IFNAR1-targeting monoclonal antibody in Phase Ib for systemic lupus erythematosus, and QX008N, a humanized IgG1 monoclonal antibody targeting thymic stromal lymphopoietin, also in Phase Ib for moderate-to-severe asthma and COPD. Qyuns is also developing several compounds at an earlier stage, including QX007N, which targets IL-33 for COPD and asthma; QX013N, aimed at c-kit for CSU; and QX010N, an IL-31R inhibitor for pruritus. Beyond its drug development endeavors, the company engages in the research, development, and manufacturing of pharmaceutical products, and provides specialized technical consultation services.
Key statistics
Avg. volume
150.45K
Market cap
HK$3.75B
P/E Ratio
5.92
Price-to-sales ratio
3.12
Enterprise value
CN¥3.56B
Free cash flow yield
16.12%
Debt-to-equity ratio
0.80
Return on equity
70.24%
ROIC
36.16%
Beta
1.47
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥786.08M
Earnings per share
CN¥1.37
Free cash flow
CN¥392.23M
Net profit margin
53.30%
Gross margin
88.64%
EBITDA
CN¥351.00M
Revenue growth
395.03%
Similar securities
This is not an investment recommendation
How to buy Qyuns Therapeutics from India
Indian residents can buy Qyuns Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Qyuns Therapeutics and place an order
Find Qyuns Therapeutics by name or by its ticker, 2509, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Qyuns Therapeutics trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Qyuns Therapeutics position in HKD and INR. Qyuns Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Qyuns Therapeutics from India
Trading and taxes when buying Qyuns Therapeutics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneQyuns Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Qyuns Therapeutics stock?
Yes. Qyuns Therapeutics (2509) has been listed on the Hong Kong Stock Exchange since 2024, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Qyuns Therapeutics share cost in rupees?
One Qyuns Therapeutics share is HK$16.77 — about ₹205 at an HKD/INR rate of 12.23 on 25 Sep 2026. Both the Qyuns Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Qyuns Therapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Qyuns Therapeutics?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Qyuns Therapeutics shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Qyuns Therapeutics price. Paasa issues a capital-gains statement for your return.
Does Qyuns Therapeutics pay a dividend?
No. Qyuns Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Qyuns Therapeutics from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Qyuns Therapeutics a Hong Kong SAR China company, and does that change how it is taxed?
Qyuns Therapeutics trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Qyuns Therapeutics trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Qyuns Therapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Qyuns Therapeutics holding, its cost and its closing value.
How do I sell Qyuns Therapeutics and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.